Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

References

• Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022 Sep;56(6):942–956. PubMed PMID: 35880713. doi: 10.1111/apt.17158
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5;397(10290):2212–2224. PubMed PMID: 33894145. doi: 10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537–2564. PubMed PMID: 33989548. doi: 10.1016/j.cell.2021.04.015
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793–801. PubMed PMID: 31279902. doi: 10.1016/j.jhep.2019.06.021.
   PubMed Web of Science ®Google Scholar
• Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017 Dec;67(6):1265–1273. PubMed PMID: 28803953. doi: 10.1016/j.jhep.2017.07.027.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54 e1-9; quiz e39–40. PubMed PMID: 24768810; PubMed Central PMCID: PMCPMC4208976. doi: 10.1016/j.cgh.2014.04.014.
   Web of Science ®Google Scholar
• Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023 Apr 14. PubMed PMID: 37061196. doi: 10.1016/j.jhep.2023.03.038.
   Google Scholar
• Luukkonen PK, Qadri S, Ahlholm N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022 Mar;76(3):526–535. PubMed PMID: 34710482; PubMed Central PMCID: PMCPMC8852745. doi: 10.1016/j.jhep.2021.10.013.
   PubMed Web of Science ®Google Scholar
• Nadasdi A, Gal V, Masszi T, et al. PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content. Cardiovasc Diabetol. 2023 Mar 21;22(1):64. PubMed PMID: 36944955; PubMed Central PMCID: PMCPMC10031960. doi: 10.1186/s12933-023-01792-w.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021 Oct 21;385(17):1559–1569. PubMed PMID: 34670043; PubMed Central PMCID: PMCPMC8881985. doi: 10.1056/NEJMoa2029349.
   PubMed Web of Science ®Google Scholar
• Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021 Jul;70(7):1375–1382. PubMed PMID: 33037056; PubMed Central PMCID: PMCPMC8185553. doi: 10.1136/gutjnl-2020-322786
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018 Aug;155(2):443–457 e17. PubMed PMID: 29733831. doi: 10.1053/j.gastro.2018.04.034.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017 May;65(5):1557–1565. PubMed PMID: 28130788; PubMed Central PMCID: PMCPMC5397356. doi: 10.1002/hep.29085
   PubMed Web of Science ®Google Scholar
• Bjorkstrom K, Widman L, Hagstrom H. Risk of hepatic and extrahepatic cancer in NAFLD: a population-based cohort study. Liver Int. 2022 Apr;42(4):820–828. PubMed PMID: 35152526; PubMed Central PMCID: PMCPMC9306866. doi: 10.1111/liv.15195.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study. J Clin Med. 2021 Jan 18;10(2). PubMed PMID: 33477579; PubMed Central PMCID: PMCPMC7831331. doi: 10.3390/jcm10020346
   Web of Science ®Google Scholar
• Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol. 2022 Jun;76(6):1263–1278. PubMed PMID: 35589249. doi: 10.1016/j.jhep.2022.04.002.
   PubMed Web of Science ®Google Scholar
• Peiseler M, Schwabe R, Hampe J, et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022 Oct;77(4):1136–1160. PubMed PMID: 35750137. doi: 10.1016/j.jhep.2022.06.012.
   PubMed Web of Science ®Google Scholar
• Chew NWS, Ng CH, Truong E, et al. Nonalcoholic steatohepatitis drug development pipeline: an update. Semin Liver Dis. 2022 Aug;42(3):379–400. PubMed PMID: 35709720. doi: 10.1055/a-1877-9656
   PubMedGoogle Scholar
• Majzoub AM, Nayfeh T, Barnard A, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021 Oct;54(7):880–889. PubMed PMID: 34435378; PubMed Central PMCID: PMCPMC8711247. doi: 10.1111/apt.16583
   PubMed Web of Science ®Google Scholar
• Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol. 2020;11:601290. PubMed PMID: 33381084; PubMed Central PMCID: PMCPMC7767990. doi: 10.3389/fendo.2020.601290
   PubMed Web of Science ®Google Scholar
• Stefan N, Schick F, Birkenfeld AL, et al. The role of hepatokines in NAFLD. Cell Metab. 2023 Feb 7;35(2):236–252. PubMed PMID: 36754018. doi: 10.1016/j.cmet.2023.01.006.
   PubMed Web of Science ®Google Scholar
• Keuper M, Haring HU, Staiger H. Circulating FGF21 levels in human health and metabolic disease. Exp Clin Endocrinol Diabetes. 2020 Nov;128(11):752–770. PubMed PMID: 31108554. doi: 10.1055/a-0879-2968
   PubMed Web of Science ®Google Scholar
• Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020 Nov;16(11):654–667. PubMed PMID: 32764725. doi:10.1038/s41574-020-0386-0.
   PubMed Web of Science ®Google Scholar
• Verzijl CRC, Van De Peppel IP, Struik D, et al. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Expert Opin Investig Drugs. 2020 Feb;29(2):125–133. PubMed PMID: 31899984. doi: 10.1080/13543784.2020.1708898
   PubMed Web of Science ®Google Scholar
• He L, Deng L, Zhang Q, et al. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:9729107. PubMed PMID: 28326329; PubMed Central PMCID: PMCPMC5343245. doi: 10.1155/2017/9729107.
   PubMed Web of Science ®Google Scholar
• Barb D, Bril F, Kalavalapalli S, et al. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3327–3336. PubMed PMID: 30848827; PubMed Central PMCID: PMCPMC7453039. doi: 10.1210/jc.2018-02414.
   PubMed Web of Science ®Google Scholar
• Puengel T, Lefere S, Hundertmark J, et al. Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int J Mol Sci. 2022 Jun 15;23(12). PubMed PMID: 35743140; PubMed Central PMCID: PMCPMC9224277. doi: 10.3390/ijms23126696
   Web of Science ®Google Scholar
• Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019 Dec;101:153994. PubMed PMID: 31672443. doi: 10.1016/j.metabol.2019.153994
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007 Jun;5(6):426–437. PubMed PMID: 17550778. doi: 10.1016/j.cmet.2007.05.002.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7432–7437. PubMed PMID: 17452648; PubMed Central PMCID: PMCPMC1855074. doi: 10.1073/pnas.0701600104.
   PubMed Web of Science ®Google Scholar
• Chikamatsu M, Watanabe H, Shintani Y, et al. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease. J Control Release. 2023 Feb 1:355:42–53. PubMed PMID: 36690035. doi: 10.1016/j.jconrel.2023.01.039.
   PubMed Web of Science ®Google Scholar
• Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014 Nov;147(5):1073–83 e6. PubMed PMID: 25083607; PubMed Central PMCID: PMCPMC4570569. doi: 10.1053/j.gastro.2014.07.044.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang YE, Chang JY, et al. An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res. 2016;8(11):4750–4763. PubMed PMID: 27904677; PubMed Central PMCID: PMCPMC5126319.
   PubMed Web of Science ®Google Scholar
• Tillman EJ, Brock WJ, Rolph T. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179(7):1384–1394. PubMed PMID: 34773249; PubMed Central PMCID: PMCPMC9306736. doi: 10.1111/bph.15725.
   PubMed Web of Science ®Google Scholar
• Stanislaus S, Hecht R, Yie J, et al. A novel fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology. 2017 May 1;158(5):1314–1327. PubMed PMID: 28324011. doi: 10.1210/en.2016-1917.
   PubMed Web of Science ®Google Scholar
• Veniant MM, Komorowski R, Chen P, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology. 2012 Sep;153(9):4192–4203. PubMed PMID: 22798348. doi: 10.1210/en.2012-1211
   PubMed Web of Science ®Google Scholar
• Zhang S, Yu D, Wang M, et al. FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. Biomed Pharmacother. 2018 Jul;103:1516–1525. PubMed PMID: 29864937. doi: 10.1016/j.biopha.2018.03.100
   PubMed Web of Science ®Google Scholar
• Liu C, Schonke M, Spoorenberg B, et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife. 2023 Jan 17; 12. PubMed PMID: 36648330. doi:10.7554/eLife.83075
   Web of Science ®Google Scholar
• Le CT, Nguyen G, Park SY, et al. LY2405319, an analog of fibroblast growth factor 21 ameliorates alpha-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. PLoS One. 2018;13(2):e0192146. PubMed PMID: 29444136; PubMed Central PMCID: PMCPMC5812602. doi: 10.1371/journal.pone.0192146
   PubMed Web of Science ®Google Scholar
• Xu P, Zhang Y, Liu Y, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta/smad2/3 and NF-kappaB signaling pathways. Toxicol Appl Pharmacol. 2016 Jan 1;290:43–53. PubMed PMID: 26592322. doi: 10.1016/j.taap.2015.11.012
   PubMed Web of Science ®Google Scholar
• Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 2016 Mar 8;23(3):427–440. PubMed PMID: 26959184. doi: 10.1016/j.cmet.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019 Jan;27(1):41–49. PubMed PMID: 30520566; PubMed Central PMCID: PMCPMC6587787. doi: 10.1002/oby.22344
   PubMed Web of Science ®Google Scholar
• Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013 Sep 3;18(3):333–340. PubMed PMID: 24011069. doi: 10.1016/j.cmet.2013.08.005.
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Charles ED, Sanyal AJ, et al. The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021 May;104:106335. PubMed PMID: 33657443. doi: 10.1016/j.cct.2021.106335.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019 Dec 22;392(10165):2705–2717. PubMed PMID: 30554783. doi: 10.1016/S0140-6736(18)31785-9.
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Sanyal AJ, Nakajima A, et al. Pegbelfermin in Patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin Gastroenterol Hepatol. 2023 Apr 23. PubMed PMID: 37088458. doi:10.1016/j.cgh.2023.04.012
   Google Scholar
• Loomba R, Sanyal AJ, Nakajima A, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clin Gastroenterol Hepatol. 2023 Apr 23. PubMed PMID: 37088457. doi:10.1016/j.cgh.2023.04.011
   Google Scholar
• Brown EA, Minnich A, Sanyal AJ, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 2023 Apr;5(4):100661. PubMed PMID: 36866389; PubMed Central PMCID: PMCPMC9971179. doi: 10.1016/j.jhepr.2022.100661.
   PubMedGoogle Scholar
• Loomba R, Lawitz EJ, Frias JP, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120–132. PubMed PMID: 36521501. doi: 10.1016/S2468-1253(22)00347-8.
   PubMedGoogle Scholar
• Pan Q, Lin S, Li Y, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021 Jan;63:103202. PubMed PMID: 33421947; PubMed Central PMCID: PMCPMC7806870. doi: 10.1016/j.ebiom.2020.103202
   PubMed Web of Science ®Google Scholar
• Jin L, Lin Z, Xu A. Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk. Diabetes Metab J. 2016 Feb;40(1):22–31. PubMed PMID: 26912152; PubMed Central PMCID: PMCPMC4768047. doi: 10.4093/dmj.2016.40.1.22
   PubMed Web of Science ®Google Scholar
• Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol. 2015;6:133. PubMed PMID: 26379627; PubMed Central PMCID: PMCPMC4553397. doi: 10.3389/fendo.2015.00133
   PubMed Web of Science ®Google Scholar
• Brahma MK, Adam RC, Pollak NM, et al. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res. 2014 Nov;55(11):2229–2241. PubMed PMID: 25176985; PubMed Central PMCID: PMCPMC4617126. doi: 10.1194/jlr.M044784.
   PubMed Web of Science ®Google Scholar
• Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. PubMed PMID: 23771152. doi: 10.1038/ncomms3019.
   PubMed Web of Science ®Google Scholar
• Ruan CC, Kong LR, Chen XH, et al. A(2A) receptor activation attenuates hypertensive cardiac remodeling via promoting brown adipose tissue-derived FGF21. Cell Metab. 2018 Sep 4;28(3):476–489 e5. PubMed PMID: 30017353. doi: 10.1016/j.cmet.2018.06.013.
   PubMed Web of Science ®Google Scholar
• Liu SQ, Roberts D, Kharitonenkov A, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013 Sep 26:3:2767. PubMed PMID: 24067542; PubMed Central PMCID: PMCPMC3783882. Northwestern University. doi: 10.1038/srep02767.
   PubMed Web of Science ®Google Scholar
• Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021 Jul;110(7):921–937. PubMed PMID: 32696080; PubMed Central PMCID: PMCPMC8238775. doi: 10.1007/s00392-020-01709-7
   PubMed Web of Science ®Google Scholar
• Sommakia S, Almaw NH, Lee SH, et al. FGF21 (Fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022 Mar;15(3):e008910. PubMed PMID: 34865514; PubMed Central PMCID: PMCPMC8930477. doi: 10.1161/CIRCHEARTFAILURE.121.008910.
   PubMed Web of Science ®Google Scholar
• Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond). 2015 Jan;39(1):121–129. PubMed PMID: 24813368. doi: 10.1038/ijo.2014.76
   PubMed Web of Science ®Google Scholar
• Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009 Jan;58(1):250–259. PubMed PMID: 18840786; PubMed Central PMCID: PMCPMC2606881. doi: 10.2337/db08-0392
   PubMed Web of Science ®Google Scholar
• Kaufman A, Abuqayyas L, Denney WS, et al. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep Med. 2020 Jul 21;1(4):100057. PubMed PMID: 33205064; PubMed Central PMCID: PMCPMC7659583. doi: 10.1016/j.xcrm.2020.100057.
   PubMedGoogle Scholar
• Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021 Jul;27(7):1262–1271. PubMed PMID: 34239138. doi: 10.1038/s41591-021-01425-3.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Ruane PJ, Freilich B, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023 Jan;5(1):100563. PubMed PMID: 36644237. PubMed Central PMCID: PMCPMC9832280. doi: 10.1016/j.jhepr.2022.100563.
   PubMedGoogle Scholar
• Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 Oct;71(4):823–833. PubMed PMID: 31300231. doi: 10.1016/j.jhep.2019.04.019.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology. 2019 Aug;70(2):522–531. PubMed PMID: 30549292; PubMed Central PMCID: PMCPMC6570584. doi: 10.1002/hep.30418
   PubMed Web of Science ®Google Scholar
• Tillman EJ, Shringarpure R, Neff G, et al. Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study [Poster]. International Liver Congress (EASL), London. 2022.
   Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020 Jul;73(1):26–39. PubMed PMID: 32147362. doi: 10.1016/j.jhep.2020.02.027.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baselinedata from the STELLAR trials. Hepatology. 2019 Nov;70(5):1521–1530. PubMed PMID: 31271665. doi: 10.1002/hep.30842
   PubMed Web of Science ®Google Scholar
• Harrison SA, Frias J, Neff G, et al. Efruxifermin (EFX) in nonalcoholic steatohepatitis with fibrosis: results from a randomized, double-blind, placebo-controlled, phase 2b trial (HARMONY) [Abstract]. AASLD The Liver Meeting, Boston. 2022 Nov.
   Google Scholar
• Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets. 2021 Oct;25(10):889–895. PubMed PMID: 34727818. doi: 10.1080/14728222.2021.1999416
   PubMed Web of Science ®Google Scholar
• Raja A, Park I, Haq F, et al. FGF19–FGFR4 signaling in hepatocellular carcinoma. Cells. 2019 Jun 4;8(6):536. PubMed PMID: 31167419; PubMed Central PMCID: PMCPMC6627123. doi: 10.3390/cells8060536.
   PubMed Web of Science ®Google Scholar
• Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3143–3148. PubMed PMID: 22315431; PubMed Central PMCID: PMCPMC3286969. doi: 10.1073/pnas.1200797109.
   PubMed Web of Science ®Google Scholar
• Li X, Stanislaus S, Asuncion F, et al. FGF21 is not a major mediator for bone homeostasis or metabolic actions of PPARalpha and PPARgamma agonists. J Bone Miner Res. 2017 Apr;32(4):834–845. PubMed PMID: 27505721. doi: 10.1002/jbmr.2936.
   PubMed Web of Science ®Google Scholar
• Wiering L, Tacke F. Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol. 2023 Jan 1;256(1). PubMed PMID: 36259984. doi: 10.1530/JOE-22-0194.
   PubMedGoogle Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Dec 14;394(10215):2184–2196. PubMed PMID: 31813633. doi: 10.1016/S0140-6736(19)33041-7.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019 Nov 30;394(10213):2012–2024. PubMed PMID: 31727409. doi: 10.1016/S0140-6736(19)32517-6.
   PubMed Web of Science ®Google Scholar
• Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. Aaps J. 2014 Jul;16(4):658–673. PubMed PMID: 24764037; PubMed Central PMCID: PMCPMC4070270. doi: 10.1208/s12248-014-9599-2.
   PubMed Web of Science ®Google Scholar
• Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45(Suppl 1):43–60. PubMed PMID: 32910487; PubMed Central PMCID: PMCPMC7540535. doi: 10.1111/jcpt.13225
   PubMedGoogle Scholar
• Loomba R, Ratziu V, Harrison SA, et al. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology. 2022 Mar;162(3):680–688. PubMed PMID: 34822801; PubMed Central PMCID: PMCPMC9683540. doi: 10.1053/j.gastro.2021.10.051
   PubMed Web of Science ®Google Scholar